Method of treating graft versus host disease
View Patent ↗A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1 bright cells and/or progeny thereof and/or soluble factors derived therefrom.
1. A method for preventing the development of GvHD complications in a mammalian patient which comprises administering to the mammal (a) a population of cells enriched for STRO-1 bright cells and (b) precursors of bone marrow lineage cells, wherein the population of cells enriched for STRO-1 bright cells is administered prior to administration of the precursors of bone marrow lineage cells.
2. A method for treating GvHD complications in a mammalian patient which comprises administering to the mammal (a) a population of cells enriched for STRO-1 bright cells and (b) precursors of bone marrow lineage cells, wherein the population of cells enriched for STRO-1 bright cells is administered after administration of the precursors of bone marrow lineage cells.
3. The method according to claim 1 or 2 , wherein the precursors of bone marrow lineage cells are allogeneic cells administered to the mammal to treat a malignant or genetic disease of the blood.
4. A method according to claim 1 or 2 , wherein the STRO-1 bright cells are allogeneic.
5. A method according to claim 1 or 2 , wherein the population of cells enriched for STRO-1 bright cells is administered systemically.
6. The method according to claim 5 , wherein the population of cells enriched for STRO-1 bright cells is administered by intravenous injection.
7. The method of claim 1 or 2 , comprising administering between 0.1×10 6 to 5×10 6 STRO-1 bright cells.
8. The method of claim 1 or 2 , comprising administering between 0.3×10 6 to 2×10 6 STRO-1 bright cells.
9. The method of claim 1 or 2 , comprising administering a low dose of STRO-1 bright cells, wherein the low dose of STRO-1 bright cells comprises between 0.1×10 5 and 0.5×10 6 STRO-1 bright cells.
10. The method of claim 1 or 2 , comprising administering a low dose of STRO-1 bright cells, wherein the low dose of STRO-1 bright cells comprises about 0.3×10 6 STRO-1 bright cells.
11. The method of claim 1 or 2 , wherein the population enriched for STRO-1 bright cells are administered once weekly or less often.
12. The method according to claim 1 or 2 , wherein the mammal is suffering from aplastic anemia, myelofibrosis, or bone marrow failure following chemotherapy and radiation therapy.
13. The method according to claim 1 or 2 , further comprising administering an immunosuppressive drug to the mammal.
14. The method according to claim 1 or 2 , wherein the mammal is a human.
15. The method according to claim 1 or 2 , wherein the population of cells enriched for STRO-1 bright cells is culture expanded prior to administration.